Pioneer Hi Bred International issued US patent for 'maize variety hybrid X03A157;' patent filed on May 25, 2010

ALEXANDRIA, Virginia , April 29, 2014 () – United States Patent no. 8,710,312, issued on April 29, was assigned to Pioneer Hi Bred International Inc (Johnston, Iowa).

"Maize variety hybrid X03A157" was invented by Matthew David Smalley (Noblesville, Ind.), Mario Rosario Carlone Jr. (Princeton, Ill.) and Travis A. Lee (Hanston, Kan.).

According to the abstract* released by the U.S. Patent & Trademark Office: "A novel maize variety designated X03A157 and seed, plants and plant parts thereof, produced by crossing Pioneer Hi-Bred International, Inc. proprietary inbred maize varieties. Methods for producing a maize plant that comprises crossing hybrid maize variety X03A157 with another maize plant. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into X03A157 through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. This invention relates to the maize variety X03A157, the seed, the plant produced from the seed, and variants, mutants, and minor modifications of maize variety X03A157. This invention further is relates to methods for producing maize varieties derived from maize variety X03A157."

The patent was filed on May 25, 2010, under Application No. 12/786,534.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8710312&OS=8710312&RS=8710312

For any query with respect to this article or any other content requirement, please contact Editor at htsyndication@hindustantimes.com

(c) 2014 US Fed News (HT Syndication)

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.